Robeco Institutional Asset Management B.V. Grows Stock Holdings in Axon Enterprise, Inc $AXON

Robeco Institutional Asset Management B.V. lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 28.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,197 shares of the biotechnology company’s stock after acquiring an additional 24,431 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Axon Enterprise were worth $79,799,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Flaharty Asset Management LLC purchased a new stake in Axon Enterprise during the 1st quarter worth $33,000. Hemington Wealth Management raised its position in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 17 shares during the period. Whipplewood Advisors LLC lifted its stake in shares of Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Axon Enterprise during the second quarter worth about $37,000. Finally, NewSquare Capital LLC boosted its position in shares of Axon Enterprise by 96.2% in the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $626.65 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The business has a 50 day moving average price of $580.16 and a two-hundred day moving average price of $690.88. The firm has a market cap of $49.45 billion, a PE ratio of 198.31, a price-to-earnings-growth ratio of 18.61 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The business’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.45 earnings per share. Sell-side analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on AXON. Morgan Stanley dropped their target price on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Cowen restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Barclays dropped their price objective on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Royal Bank Of Canada began coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They set an “outperform” rating and a $860.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a research note on Monday, September 29th. Fifteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $798.67.

Insider Transactions at Axon Enterprise

In other news, Director Jeri Williams sold 100 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total value of $55,063.00. Following the completion of the sale, the director owned 1,316 shares of the company’s stock, valued at approximately $724,629.08. The trade was a 7.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the sale, the president owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 50,540 shares of company stock valued at $28,494,638 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.